Jump to main content
博士論文

A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience 181 1

Icons representing 博士論文
The cover of this title could differ from library to library. Link to Help Page

A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience 1

Persistent ID (NDL)
info:ndljp/pid/11679186
Material type
博士論文
Author
渡邉, 純一郎
Publisher
-
Publication date
2021-01-20
Material Format
Digital
Capacity, size, etc.
-
Name of awarding university/degree
順天堂大学,博士(医学)
View All

Notes on use at the National Diet Library

本資料は、掲載誌(URI)等のリンク先にある学位授与機関のWebサイトやCiNii DissertationsLeave the NDL website. から、本文を自由に閲覧できる場合があります。

Notes on use

Note (General):

2020年度

Table of Contents

Provided by:国立国会図書館デジタルコレクションLink to Help Page
  • 2024-12-06 再収集

  • 2024-12-06 再収集

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type
博士論文
Volume
181 1
Author/Editor
渡邉, 純一郎
Author Heading
Publication Date
2021-01-20
Publication Date (W3CDTF)
2021-01-20
Alternative Title
(末梢血リンパ球数の維持はHER2陰性進行再発乳癌患者に対するエリブリン療法(再投与も含む)の全生存期間に対する効果予測因子である:単施設による観察研究)
Periodical title
Breast Cancer Research and Treatment
Degree grantor/type
順天堂大学